RxDoctor Payments Data

Daniel Skubick, MD

Neurology · North Wales, PANPI 1568441665

Payments from drug & device makers

$343in general payments, 2019–2025

Across 18 payments — averaging $19.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$200
  • Lilly USA, LLC$92
  • Pfizer$14
  • Novartis$13
  • Boston Scientific$12
  • Impel Pharmaceuticals Inc.$12

What the payments were for

  • Food & beverage$33196%
  • Education$124%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)13$200
Lilly USA, LLC1$92
Pfizer1$14
Novartis1$13
Boston Scientific1$12
Impel Pharmaceuticals Inc.1$12

How this compares

$343 in reported general payments places this provider in the 35th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$269,144
Medicare patients
175
Services billed
18,501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KeveyisDichlorphenamide13$392,571
BelbucaBuprenorphine Hcl43$34,268
Aimovig AutoinjectorErenumab-Aooe31$27,241
BotoxOnabotulinumtoxina11$14,254
Emgality PenGalcanezumab-Gnlm20$13,828
Morphine Sulfate ErMorphine Sulfate126$5,108
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen121$4,283
Fentanyl15$2,849
Buprenorphine Hcl67$1,574
Oxycodone Hcl79$1,572
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine29$1,498
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen105$1,495
Gabapentin63$1,349
Naloxone Hcl15$835
Carisoprodol17$814

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox$200$14,25411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 941 neurology providers in Pennsylvania.

Other neurology in North Wales

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →